A Double-Blind Trial to Test if NAD+ Improves Cognition

Abstract

Pharmaceutical companies market nicotinamide adenine dinucleotide (NAD+) as a supplement that helps support cognitive functioning in aging adults, selling it as a potential shield against age-related decline and Alzheimer’s disease. Although clinical trials are emerging, current research on its efficacy remains limited.